评估TDApp:一个基于AI的临床决策支持系统,用于ADHD治疗建议
Evgenia Baykova1, Òscar Raya2, Cristina Lombardía1
1Institute of Health Care (ICS-IAS), Girona, Spain.
Frontiers in psychiatry
|September 8, 2025
概括
临床决策支持系统TDApp提供个性化的ADHD治疗建议. 与传统的临床实践指南相比,它提供了更加多样化和量身定制的方法,增强了共享决策.
科学领域:
- 人工智能在医学中的应用
- 临床决策支持系统 临床决策支持系统
- 药物基因组学 药物基因组学
背景情况:
- 临床实践指南 (CPG) 面临的局限性包括过时,缺乏个性化和患者参与不足,可能导致治疗结果不足最佳.
- APPRAISE-RS是GRADE启发式的调整,利用象征性AI生成自动化,更新,个性化,参与性和解释性的治疗建议.
- TDApp是一个临床决策支持系统 (CDSS),旨在实施APPRAISE-RS用于注意力缺陷/多动症障碍 (ADHD) 治疗.
研究的目的:
- 评估TDApp产生的治疗建议的疗效和特征,与ADHD现有的CPG相比.
- 评估TDApp的建议与多个已建立的CPG的多样性和一致性.
- 确定TDApp作为ADHD管理中共享治疗决策的工具的潜力.
主要方法:
- 两项临床试验分别招募了33名和32名多动症患者,以启动或修改治疗.
- 将TDApp的建议与来自五个国际组织的CPG进行了比较.
- 使用布劳指数分析了治疗多样性,通过药物认可重叠评估了一致性,并使用树突图可视化了推距离.
主要成果:
- TDApp为50-75%的患者提供了有利的治疗建议,评估了10多种药物,经常建议使用安非他胺衍生物.
- 与CPG相比,TDApp产生了8-12个不同的建议,其多样性指数比CPG高 (0.70-0.88).
- 丹德罗图分析显示,TDApp的建议与CPG分别聚集在一起,这表明了不同的方法.
结论:
- TDApp作为一个先进的CDSS原型,提供自动化,个性化和解释性的ADHD治疗建议.
- 该系统展示了对传统CPG的有希望的替代方案,促进了临床医生和患者之间更好的共享决策.
- TDApp的方法为ADHD管理提供了更大的个性化和治疗选择的多样性.
更多相关视频
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
10.9K
10:02Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
Published on: March 12, 2020
16.6K
相关概念视频
Attention-Deficit/Hyperactivity Disorder
792
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
792
Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
Therapeutic Drug Monitoring: Affecting Factors
202
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
202
Therapeutic Drug Monitoring: Overview and Classification
315
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
315
